BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results

By WebmasterApril 16, 2019November 1st, 2024No Comments

Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
Research Findings Accepted for Publication in Journal of Clinical Psychopharmacology

See more here

Previous PostMelior Pharmaceuticals Announces Positive Results in Phase 2B Study with Tolimidone for Type 2 Diabetes
Next PostPalvella Therapeutics raises $3M to advance rare disease drug

Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostMelior Pharmaceuticals Announces Positive Results in Phase 2B Study with Tolimidone for Type 2 Diabetes

Next PostPalvella Therapeutics raises $3M to advance rare disease drug